Model-based neutrophil-guided dose adaptation in chemotherapy: Evaluation of predicted outcome with different types and amounts of information

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 3, 2010, Pages 234-242

  Wallin, Johan E ^a   Friberg, Lena E ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; TOPOTECAN;

ADAPTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; COMPUTER SIMULATION; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; DRUG INFORMATION; NEUTROPENIA; NEUTROPHIL COUNT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDBACK, PHYSIOLOGICAL; HUMANS; INDIVIDUALIZED MEDICINE; LEUKOCYTE COUNT; MODELS, BIOLOGICAL; NEUTROPENIA; NEUTROPHILS;

EID: 77149142587     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00520.x     Document Type: Conference Paper

References (33)

1. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003 21 : 4524 4531.
2. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966 64 : 328 340.
3. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004 100 : 228 237.
4. Vepesid (Bristol Myers-Squibb) Approved Drug Label NDA 018768. Washington, DC, 1999.
5. Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003 89 : 1837 1842.
6. Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005 6 : 669 677.
7. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999 80 : 1763 1766.
8. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996 14 : 257 267.
9. Nguyen L, Chatelut E, Chevreau C, Tranchand B, Lochon I, Bachaud JM et al. Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 1998 41 : 125 132.
10. Arbuck SG, Douglass HO, Crom WR, Goodwin P, Silk Y, Cooper C et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 1986 4 : 1690 1695.
11. Stewart CF, Arbuck SG, Fleming RA, Evans WE. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 1990 8 : 1874 1879.
12. Stewart CF, Fleming RA, Arbuck SG, Evans WE. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 1990 50 : 6854 6856.
13. de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet 2005 44 : 147 173.
14. Evene E, Chatelut E, Tranchand B, Canal P, Lochon I, Iliadis A et al. Bayesian estimation of pharmacokinetic parameters of etoposide. Bull Cancer 1997 84 : 699 703.
15. Tranchand B, Amsellem C, Chatelut E, Freyer G, Iliadis A, Ligneau B et al. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 1999 43 : 316 322.
16. Rousseau A, Marquet P, Debord J, Sabot C, Lachatre G. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000 38 : 315 353.
17. Friberg LE, Karlsson MO. Mechanistic models for myelosuppression. Invest New Drugs 2003 21 : 183 194.
18. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002 20 : 4713 4721.
19. Karlsson MO, Anehall T, Friberg LE, Henningsson A, Kloft C, Sandstrom M et al. Pharmacokinetic/pharmacodynamic modelling in oncological drug development. Basic Clin Pharmacol Toxicol 2005 96 : 206 211.
20. Wallin JE, Friberg LE, Karlsson MO. A tool for neutrophil guided dose adaptation in chemotherapy. Comput Methods Programs Biomed 2009 93 : 283 291.
21. Hansson EK, Wallin JE, Lindman H, Sandstrom M, Karlsson MO, Friberg LE. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 2009. Epub ahead of print.
22. Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 2006 58 : 143 156.
23. Toffoli G, Corona G, Sorio R, Robieux I, Basso B, Colussi AM et al. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol 2001 52 : 511 519.
24. Beal SL, Sheiner LB. NONMEM Users Guides. GloboMax, Inc., Hanover, MD, 1989-2006.
25. Beal SL, Sheiner LB. NONMEM Users Guide, NONMEM project group. University of California, San Francisco, CA, 1992.
26. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 9 : 503 512.
27. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002 16 : 253 262.
28. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 1991 9 : 1480 1486.
29. Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 1989 45 : 226 233.
30. Miller AA, Tolley EA, Niell HB. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer. Clin Cancer Res 1998 4 : 1705 1710.
31. Conley BA, Egorin MJ, Sinibaldi V, Sewack G, Kloc C, Roberts L et al. Approaches to optimal dosing of hexamethylene bisacetamide. Cancer Chemother Pharmacol 1992 31 : 37 45.
32. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000 356 : 1384 1391. (Pubitemid 30800206)
33. Kloft C, Wallin JE, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 2006 12 : 5481 5490.